Publications by authors named "Lingaraju C"
Article Synopsis
- Pediatric brain tumor prognosis is currently poor, but there is hope that CAR T cell therapy could improve outcomes, as indicated by a study involving the first six treated patients in a clinical trial (NCT04510051).
- Interim results show that three out of five evaluable patients experienced some temporary clinical benefits, while overall there were no serious side effects from the treatment, despite some patients experiencing common issues like cytopenias.
- Analysis of immune responses revealed interesting interactions between CAR T cells and the patient's immune system, highlighting differences in T cell populations in the cerebrospinal fluid compared to peripheral blood, suggesting the need for careful sampling in future studies.
Cytomegalovirus (CMV) reactivation after hematopoietic cell transplantation (HCT) augments adaptive (CD56NKG2CCD57) natural killer (NK) and CMV-specific T cells, with potential antitumor effects. Our recent work found an association between higher abundance of adaptive NK cells after auto-HCT and lower risk of relapse in patients with multiple myeloma. Triplex vaccine is a recombinant modified vaccinia Ankara expressing immunodominant CMV antigens, which significantly enhanced CMV-specific T-cell immune responses in allo-HCT recipients.
View Article and Find Full Text PDFBackground: Few studies have compared the surgical outcomes between tubercular empyema (TE) and nontubercular empyema (NTE), which were limited by a small sample size. We conducted this study with the objective of comparing the surgical outcomes of patients with tuberculous and nontuberculous empyema.
Materials And Methods: This is a retrospective analysis of 285 consecutively operated cases of TE and NTE over 5 years conducted in a tertiary care center in New Delhi, India.
Background: Triplex vaccine was developed to enhance cytomegalovirus (CMV)-specific T cells and prevent CMV reactivation early after hematopoietic stem cell transplant (HCT).
Objective: To determine the safety and efficacy of Triplex.
Design: First-in-patient, phase 2 trial.
Early cytomegalovirus (CMV) reactivation remains a significant cause of morbidity and mortality in allogeneic hematopoietic cell transplant (HCT) recipients. CMVPepVax is an investigational peptide vaccine designed to control CMV infection in HCT recipients seropositive for CMV by stimulating the expansion of T cell subsets that target the CMV tegument protein pp65. In a randomized Phase Ib pilot trial (ClinicalTrials.
View Article and Find Full Text PDF